EGAN and PSR sign Intention to Collaborate
8 October 2010,
PSR and EGAN signed an intention to collaborate in the field of clinical research. PSR is a leading expert in Orphan drug development.
Both PSR and EGAN acknowledge the importance of involving patient groups at an early stage in the development of Orphan drugs and their clinical study programs. The advantages range from valuable input in the creation of study protocols to having access to patients and overcoming the logistical challenges of sparsely distributed patients.
EGAN will be able to act as an intermediate partner in order to establish contacts with patient groups in Europe, whilst PSR will be able to involve those patient groups as early as possible in drug development programs.
PSR and EGAN will be intensifying their relationship and collaborate on a project-by-project basis whenever possible and appropriate.